A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Study sponsor: Outlook Therapeutics, Inc. · OTLK
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-07-23Actual
Enrollment · participants61Actual
Source updated2025-03-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.